FDA ends shortage of Ozempic and Wegovy, but compounding pharmacies must stop producing unapproved versions, potentially impacting patients who relied on more affordable options.
FDA ends shortage of Ozempic and Wegovy, but compounding pharmacies must stop producing unapproved versions, potentially impacting patients who relied on more affordable options.
